GH Research PLC (NASDAQ:GHRS) Short Interest Update

GH Research PLC (NASDAQ:GHRS) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,280,000 shares, a growth of 11.8% from the December 15th total of 2,040,000 shares. Based on an average daily volume of 72,900 shares, the short-interest ratio is presently 31.3 days. Approximately 7.5% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of GH Research in a report on Friday, January 10th. Canaccord Genuity Group dropped their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, November 18th.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP boosted its holdings in GH Research PLC (NASDAQ:GHRS) by 19.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,966,726 shares of the company’s stock after purchasing an additional 656,163 shares during the quarter. GH Research makes up 16.7% of Lynx1 Capital Management LP’s portfolio, making the stock its 3rd biggest holding. Lynx1 Capital Management LP owned approximately 7.62% of GH Research worth $46,252,000 as of its most recent SEC filing. Institutional investors own 56.90% of the company’s stock.

GH Research Trading Up 3.3 %

Shares of NASDAQ:GHRS traded up $0.28 on Friday, hitting $8.88. The company had a trading volume of 61,082 shares, compared to its average volume of 78,587. The company has a market cap of $462.01 million, a PE ratio of -11.24 and a beta of 0.84. The business has a 50 day moving average of $8.45 and a 200 day moving average of $9.07. GH Research has a 52-week low of $5.50 and a 52-week high of $14.99.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).